Safety and Effectiveness of Nivolumab in Recurring Kidney Cancer Participants
Completed
- Conditions
- Kidney CancerRenal Cancer
- Interventions
- Other: Non-Interventional
- Registration Number
- NCT03568435
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
A non-interventional, medical record review of clinical data collected from Japanese participants with recurring kidney cancer
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 212
Inclusion Criteria
- A patient with RCC with distant metastasis treated for the first time with nivolumab
Read More
Exclusion Criteria
- Patients who have participated in some trials with immuno-checkpoint blockade before or after treatment with nivolumab after diagnosis with RCC
Other protocol defined inclusion/exclusion criteria could apply
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Participants with metastatic RCC taking nivolumab Non-Interventional Specified dose on specified day
- Primary Outcome Measures
Name Time Method Disease free survival 36 months Progression free survival rate 36 months Objective response rate 36 months Duration of response 36 months Incidence of adverse events 36 months Incidence of serious adverse events 36 months Overall survival status 36 months Best overall response 36 months
- Secondary Outcome Measures
Name Time Method Distribution of socio-demographic characteristics 36 months Distribution of clinical characteristics 36 months
Trial Locations
- Locations (1)
Local Institution - 0001
🇯🇵Tokyo, Japan